Improved diagnosis of meningococcal, pneumococcal and group A streptococcal infections

Please note, this collection consists of blood clots but it is listed as plasma. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ dTpa-IPV vaccine (Boostrix Polio) compared with Sanofi Pasteur MSD’s dTpa-IPV vaccine (Repevax), when coadministered with GSK Biologicals’ MMR vaccine (Priorix) in 3 and 4-year-old healthy children.

Please note, this collection consists of blood clots but it is listed as plasma. Study to demonstrate the efficacy of GlaxoSmithKline Biologicals’ quadrivalent seasonal influenza candidate vaccine GSK2321138A (FLU D-QIV), administered intramuscularly in children 9 to 35 months of age.

Please note, this collection consists of blood clots but it is listed as plasma. A new vaccine has been developed by Novartis Vaccines and Diagnostics S.r.l. (“Novartis Vaccines”) aimed at preventing MenB disease. The vaccine is “investigational”, meaning that it has been approved for use in the study but that it is not licensed for routine use. In 2008-2009 a study of this MenB vaccine, enrolling 1,800 children, was conducted in the UK and other European countries. Of these, 1,510 children participated in a follow-on study, receiving a further dose of MenB at 12, 18, or 24 months of age. In addition 3 control groups received 2 doses of the MenB vaccine, 2 months apart, at 12, 18 or 24 months of age. Children who have completed this study are now being approached to take part in a second ‘follow-on’ study in which the majority of children will receive one further dose of the MenB vaccine at around 4 years of age. The aim of this follow-on study is to assess whether children immunised as infants and/or toddlers with the MenB vaccine have maintained high levels of antibodies against MenB germs until they are around 4 years of age. We would also like to assess how well children respond to a further dose of the MenB vaccine. In addition we will be monitoring the safety of the MenB vaccine.

Please note, this collection consists of blood clots but it is listed as plasma. During the initial study your child received one of 2 pneumococcal vaccines; either the 7-valent pneumococcal vaccine (PCV7) which protects against 7 types of pneumococcal bacteria, or the new 13-valent pneumococcal vaccine (PCV13) protecting against 13 types of pneumococcus which has recently replaced PCV7 in the routine immunisation schedule. The PCV13 vaccine has been shown to produce an immune response against 13 types of pneumococcus and therefore provides a broader level of protection than the PCV7 vaccine. It is now important to determine how well the immune response to the PCV13 vaccine persists throughout childhood. To do this we would like to take a sample of blood from children, who participated in the original study, when they are approximately 3 ½ years of age. We would also like to study the response to a dose of PCV13 vaccine when given to children who were immunised with either PCV7 or PCV13 as an infant.

Please note, this collection consists of blood clots but it is listed as plasma. A phase III open-label randomised study, to evaluate the immunogenicity and safety of the concomitant administration of V419 (PR5I) given at 2, 3 and 4 months of age with two types of meningococcal serogroup C conjugate (MCC) vaccines given at 3 an 4 months of age, and followed by the administration at 12 months of age of a combined Haemophilus influenza type b-MCC vaccine.